HLA-DRB1*03 allele is a significant predictor of anti-adalimumab antibodies formation in RA, HS, and IBD patients treated with anti-TNF therapies, contributing to variability in immunogenic responses. This evidence concerns the gene TNF and rheumatoid arthritis.